BioCryst begins patient enrollment in REDEEM-1 trial of BCX9930 for rare blood disorder

Jan. 07, 2022 9:42 AM ETBioCryst Pharmaceuticals, Inc. (BCRX)By: Ravikash, SA News Editor10 Comments

Red blood cells flowing through the blood stream

ExperienceInteriors/E+ via Getty Images

  • BioCryst Pharmaceuticals (BCRX -0.2%) said it enrolled the first patient in the REDEEM-1 pivotal trial of BCX9930 as standalone therapy for patients with paroxysmal nocturnal hemoglobinuria (PNH).
  • PNH is a rare blood disorder characterized by destruction

Recommended For You

Comments (10)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.